Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarkers in mdx5Cv Dystrophic Mice SEATTLE, March 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL. Presentation Highlights The mdx5Cv Dystrophic mouse model, a trusted, reproducible standard for Duchenne muscular dystrophy (DMD) preclinical research, was used for this study (Z)-Endoxifen improved muscle strength and motor performance in both juvenile and adult dystrophic mice Treatment enhanced resistance to contraction-induced muscle injury Favorable changes were observed in body composition, including increased lean mass and reduced fat mass Key biochemical and histologic markers of muscle damage were reduced The therapy was well tolerated with no adverse findings observed during the study Clinical Significance DMD is a progressive and ultimately fatal neuromuscular disorder characterized by ongoing muscle degeneration, inflammation, and fibrosis.
